iBB

Ana Margarida Azevedo from BERG-iBB has moved to the second step of the evaluation of Consolidator Grants of the European Research Council with a project entitled “PureMAb: Addressing the Manufacturing Challenges Faced by the Therapeutic Monoclonal Antibodies Market”. In many cases, monoclonal antibodies (mAbs) are the only treatment option for patients with life-threatening diseases such as cancer. Unfortunately, mAbs are the most expensive drugs in the world. The project aims to decrease the manufacturing costs of mAbs by exploring alternative purification methodologies such as multimodal chromatography. A microfluidic platform is developed to accelerate the screening of ligands and binding/elution conditions.